The company is governed by a board of directors.
Corinne Granger, Chair of the board:
Corinne Granger, is Director of Research and Development, over 14 years in Cosmetics and Dermatology Industries and hold several R&D positions during more than 30 years in Health Care. She set up several R&D units around the world. She is Doctor in Medicine from Bordeaux University and hold a certificate on governance of enterprises from ESSEC business school Paris.
Muriel Atias – Permanent representative BOLD – BOLD Business Opportunities for L’Oréal Development, Observer:
Muriel Atias is the Chief Investment Officer of BOLD Business Opportunities for L’Oréal Development, L’Oréal’s corporate venture capital fund aiming to take minority stakes in innovative companies and brands with high growth potential. Having graduated from the ESSEC Business School, Muriel has over 17 years of experience in mergers and acquisitions, of which 10 in an investment bank. She joined L’Oréal in 2014, first in the Corporate Finance team in charge of acquisitions for the Group then at BOLD Business Opportunities for L’Oréal Development when launched in December 2018.
Marc Delcourt, CEO and Co-founder, Board member:
Global Bioenergies, Marc Delcourt is a former student of the Ecole Normale Supérieure, biology section. After completing a thesis in North America , it is towards R & D activities in the field of bioprocess and created in 1997 the first company in the field of industrial biology, Biométhodes. He left Biométhodes in 2008, then founded Global Bioenergies.
Alain Fanet, Board member:
Alain Fanet has been an entrepreneur and executive for more than 20 years. He created two Franco-American companies in the high-tech sector: Arteris and T.sqware. He was recently Chairman and CEO of CXIgnited, an innovative company specialized in traceability of the supply channels in the luxury industry. Alain Fanet earned his PHD in Computer Science from ParisTech
Pierre Lévi – Permanent representative of METMAN CAPITAL, Board member:
Pierre Lévi performed management functions in significant international groups, such as Groupe Salins (CEO), Faurecia (Chairman and CEO) or Rhône-Poulenc/Rhodia (Deputy President). He advises several innovative companies through his holding Metman Capital. Pierre Lévi is a graduate from Ecole des Mines of Paris and Warton School (MBA).
Pierre Monsan, Board member:
Through his career, Pierre Monsan has developed expertise in catalysis and enzymatic molecular engineering, publishing over 250 scientific publications, three books and 65 patents. After co-founding BioEurope (Solabia group) (1984), BioTrade (1996) and Génibio (1998), in 2012 he created the Toulouse White Biotechnology (TWB) pre-industrial demonstrator.
Pierre Monsan acts as adviser to a number of major groups in the food industry, chemicals and cosmetics. He is a member of a number of associations and organisations such as the Académie des Technologies, the National Academy of Agriculture, the College of Fellows of the American Institute for Medical and Biological Engineering and Honorary President of the French Biotechnology Federation. He is also an professor emeritus at INSA Toulouse and a former professor at the Ecole des Mines ParisTech. Finally, Pierre Monsan is a Knight of the French Ordre du Mérite and Légion d’Honneur and an Officer of the Palmes Académiques.
